CARMIEL, Israel, March 3 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today that the Israeli Ministry of Health has completed a successful GMP (Good Manufacturing Practice) audit of the Company’s manufacturing facility in Carmiel, Israel. The audit was performed as part of the Ministry of Health’s evaluation of the company’s manufacturing process of taliglucerase alfa for the treatment of Gaucher disease.
In February 2010, the company announced Phase III data at the Lysosomal Disease Network’s WORLD symposium. The study, which reached its primary endpoint, demonstrated a mean reduction in spleen volume in both treatment arms studied (60 U/kg, 30 U/kg taliglucerase alfa) in patients with Gaucher disease in a highly significant statistical manner. In this study, taliglucerase alfa was well tolerated, no serious or severe adverse events were reported, a low (6%) level of antibody formation was found and there was no neutralizing antibody formation.
Protalix BioTherapeutics, Inc.
